<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJO</journal-id><journal-title-group><journal-title>Hans Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="epub">2167-6542</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJO.2015.42008</article-id><article-id pub-id-type="publisher-id">HJO-15536</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJO20150200000_39994217.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  抗VEGF治疗RVO合并的黄斑水肿的研究进展
  Study Progress of Unti-VEGF Treatment of Macular Edema Induced by Retinal Vein Occlusion
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>敏</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>文娟</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>06</month><year>2015</year></pub-date><volume>04</volume><issue>02</issue><fpage>42</fpage><lpage>46</lpage><history><date date-type="received"><day>Jul.</day>	<month>7th,</month>	<year>2014</year></date><date date-type="rev-recd"><day>Jul.</day>	<month>20th,</month>	<year>2014</year>	</date><date date-type="accepted"><day>Jul.</day>	<month>25th,</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   视网膜静脉阻塞(retinal vein occlusion, RVO)是仅次于糖尿病性视网膜病变的常见视网膜血管疾病,是致盲的主要原因之一。黄斑水肿(macular edema)是RVO视力损害的最主要的原因。因此黄斑水肿的治疗是RVO治疗中最重要的内容，近年来抗VEGF药物的出现为黄斑水肿的治疗提供了一种新的治疗手段，目前大量研究证实无论是在消除或者减轻黄斑水肿方面，还是在提高视力方面，玻璃体腔内注射抗VEGF药物治疗RVO黄斑水肿都是有确切疗效的。本文就近年来有关RVO合并的黄斑水肿的抗VEGF治疗研究进展综述如下。&lt;br/&gt;Retinal vein occlusion (RVO) is a common disease to cause blindness, which incidence is only next to diabetic retinopathy. The macular edema is the cause of vision loses. Therefore, the treatment of macular edema is one of the most important contents of RVO treatment. In recent years, the emergence of anti-VEGF drugs for the treatment of macular edema provides a new method. At present, a large of studies confirm whether in terms of eliminate or relieve the macular edema, or in terms of improving eyesight. Vitreous injection of anti-VEGF drug has exact curative effect. This paper reviews the recent advances in anti-VEGF treatment of macular edema secondary to retinal vein occlusion.
    
  
 
</p></abstract><kwd-group><kwd>黄斑水肿，视网膜静脉阻塞，抗VEGF治疗，联合治疗, Macular Edema</kwd><kwd> Retinal Vein Occlusion</kwd><kwd> Anti-VEGF Treatment</kwd><kwd> Combined Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>抗VEGF治疗RVO合并的黄斑水肿的研究进展<sup> </sup></title><p>刘敏，罗文娟</p><p>青岛大学，山东 青岛</p><p>Email: liumin9102@163.com</p><p>收稿日期：2015年5月29日；录用日期：2015年6月26日；发布日期：2015年6月29日</p><disp-formula id="hanspub.15536-formula4591"><graphic xlink:href="http://html.hanspub.org/file/5-2230064x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>视网膜静脉阻塞(retinal vein occlusion, RVO)是仅次于糖尿病性视网膜病变的常见视网膜血管疾病,是致盲的主要原因之一。黄斑水肿(macular edema)是RVO视力损害的最主要的原因。因此黄斑水肿的治疗是RVO治疗中最重要的内容，近年来抗VEGF药物的出现为黄斑水肿的治疗提供了一种新的治疗手段，目前大量研究证实无论是在消除或者减轻黄斑水肿方面，还是在提高视力方面，玻璃体腔内注射抗VEGF药物治疗RVO黄斑水肿都是有确切疗效的。本文就近年来有关RVO合并的黄斑水肿的抗VEGF治疗研究进展综述如下。</p><p>关键词 :黄斑水肿，视网膜静脉阻塞，抗VEGF治疗，联合治疗</p><disp-formula id="hanspub.15536-formula4592"><graphic xlink:href="http://html.hanspub.org/file/5-2230064x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. RVO引起黄斑水肿</title><p>根据其阻塞部位不同，视网膜静脉阻塞可分为视网膜分支静脉阻塞(branch retinal vein occlusion, BRVO)和视网膜中央静脉阻塞(central retinal vein occlusion, CRVO)，其患病率分别为0.1%~0.4%和0.6%~1.6%，视网膜静脉阻塞的并发症有黄斑水肿、视网膜及视盘新生血管形成、玻璃体出血及新生血管性青光眼等，其中黄斑水肿是RVO导致视力下降最主要的原因，也是其最常见的并发症，发生率为48%~67%，黄斑水肿的早期就会对患者的视力产生不良影响，此时若能使水肿尽快消退则患者的视力会得到不同程度的恢复，严重或长期的黄斑水肿会造成永久性视力损害[<xref ref-type="bibr" rid="hanspub.15536-ref1">1</xref>] 。</p><p>血–视网膜屏障 是保证视网膜进行正常功能的重要屏障，由视网膜血管和视网膜色素上皮共同组成，视网膜色素上皮细胞紧密连接构成阻止脉络膜组织液渗入视网膜的外屏障，视网膜血管内皮细胞紧密连接构成阻止血管内液渗入视网膜的内屏障，视网膜静脉阻塞时视网膜血－视网膜屏障受到严重损害，血管内的液体和大分子物质向外渗漏，液体积聚在视网膜神经上皮外丛状层，形成视网膜水肿，当病变累及黄斑区时，黄斑区视网膜内的液体异常堆积，从而引起黄斑水肿。另外，视网膜静脉阻塞，会导致毛细血管无灌注区，从而引起前列腺素、血管内皮生长因子(vascular endothelial growth factor, VEGF)等一些内源性细胞因子的释放，这些内源性细胞因子的浓度水平与视网膜血管的通透性和黄斑水肿严重程度密切相关[<xref ref-type="bibr" rid="hanspub.15536-ref2">2</xref>] 。</p></sec><sec id="s4"><title>2. 抗VEGF药物</title><p>VEGF基因家族包括VEGF-A、B、C、D和胎盘生长因子，其中VEGF-A已被证实是诱导血管再生最有效的因素，VEGF-A与受体结合触发一系列级联反应、促进血管内皮细胞分裂增殖、新生血管生成，并维持新生血管的存活，是炎症细胞趋化因子[<xref ref-type="bibr" rid="hanspub.15536-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.15536-ref4">4</xref>] 。在对RVO患者的房水和玻璃体的检测中均证实了VEGF的升高，而在BRVO中更证实了VEGF的浓度与黄斑水肿的程度呈正相关[<xref ref-type="bibr" rid="hanspub.15536-ref5">5</xref>] -[<xref ref-type="bibr" rid="hanspub.15536-ref7">7</xref>] ，因此抗VEGF治疗成为治疗RVO黄斑水肿的靶点。抗VEGF药物主要通过拮抗作用抑制新生血管形成、降低血管通透性、调控血–视网膜屏障通透性，从而达到促进视网膜内渗液吸收和改善黄斑水肿的目的[<xref ref-type="bibr" rid="hanspub.15536-ref8">8</xref>] 。</p><sec id="s4_1"><title>2.1. 哌加他尼钠(Pegaptanib, Macugen)</title><p>Macugen化学名为pegaptanib，是一个28碱基RNA适体，能特异性地与VEGF165相结合，阻断其生物活性，且不影响其他VEGF异构体的活性。Macugen于2004年11月成为第一个获得美国FDA批准治疗眼部新生血管疾病的抗VEGF药物。在Ⅱ期临床药物试验中，将Macugen玻璃体注射应用于CRVO患者中，分别给予0.3 mg、1.0 mg及安慰剂，随访30周，结果显示0.3 mg、1.0 mg Macugen组平均视力分别提高7.1个字符和9.9个字符，黄斑厚度分别减少269 μm、210 μm，安慰剂组平均视力下降3.2个字符，从而证明Macugen对于RVO黄斑水肿是安全有效的[<xref ref-type="bibr" rid="hanspub.15536-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.15536-ref10">10</xref>] 。Wroblewski等[<xref ref-type="bibr" rid="hanspub.15536-ref11">11</xref>] 将Macugen应用于BRVO患者中，BRVO患者分别给予0.3 mg、1 mg Macugen玻璃体腔内注射，54周的观察发现所有患者最佳矫正视力提高，黄斑中心凹厚度减少。</p></sec><sec id="s4_2"><title>2.2. 贝伐单抗(Bevacizumab, Avastin)</title><p>Avastin是人源化的全长VEGF单克隆抗体，可与人体内各种VEGF亚型结合，通过抑制其活性而起治疗作用，它可以有效降低VEGF浓度，减少血管渗漏，从而减轻视网膜和黄斑水肿。于2004年2月获得美国FDA批准，用于一线治疗转移性结肠癌、直肠癌。2005年Rosenfeld等[<xref ref-type="bibr" rid="hanspub.15536-ref12">12</xref>] 报道了首例玻璃体腔内注射Avastin治疗CRVO黄斑水肿，该病例因TA治疗加重了白内障和青光眼而改用Avastin治疗，治疗后1周，视力从原有的0.1提升至0.4，OCT提示黄斑水肿减轻，且持续4周，无不良反应发生。2006年Jaissle等将其用于治疗由视网膜静脉阻塞引起的黄斑水肿，对RVO的患者进行玻璃体腔注射1.25 mg Avastin，随访3个月，结果显示数天内视功能迅速改善，93%的患者提高了1行及以上视力，27%的患者提高了4行及以上视力，后极部视网膜厚度显著降低[<xref ref-type="bibr" rid="hanspub.15536-ref13">13</xref>] 。瑞典学者评价了Avastin治疗CRVO导致黄斑水肿的效果[<xref ref-type="bibr" rid="hanspub.15536-ref14">14</xref>] 。该前瞻性、双盲、随机、安慰剂对照研究入选60名患者，随访期6个月，患者按照1:1的比例，每6周1次随机接受Avastin或安慰剂玻璃体内注射。观察结果表明在减轻黄斑水肿和提高视力方面，治疗组疗效显著优于安慰剂组。Ferrara等[<xref ref-type="bibr" rid="hanspub.15536-ref15">15</xref>] 认为早期注射Avastin治疗RVO可增加视网膜血流，减少视网膜无灌注区，并且有助于减轻视网膜静脉迂曲、扩张和黄斑水肿的临床表现。</p></sec><sec id="s4_3"><title>2.3. 雷珠单抗(Ranicizumab, Lucentis)</title><p>Ranicizumab是第二代人源化的重组抗VEGF单克隆抗体片段Fab部位，其特性是对VEGF的所有亚型均有较强的亲和力，能迅速并长期地封闭VEGF-A，这使得血–视网膜屏障得以复原，黄斑厚度下降，且视力明显提高[<xref ref-type="bibr" rid="hanspub.15536-ref4">4</xref>] 。2006年Ranicizumab获得美国FDA批准，用于治疗湿性年龄相关性黄斑变性。2010 年FDA批准Ranicizumab用于治疗RVO引起的黄斑水肿。美国Brown等[<xref ref-type="bibr" rid="hanspub.15536-ref16">16</xref>] 进行了有关Ranibizumab治疗CRVO继发黄斑水肿的为期6个月的CRUISEⅢ期临床研究。该前瞻性、多中心、随机、安慰剂对照、双盲研究中，纳入了392例CRVO继发黄斑水肿的患者，按照1:1:1的比例，随机接受每月1次玻璃体内注射0.3 mg、0.5 mg的Ranibizumab或者安慰剂。结果表明，玻璃体内注射0.3 mg或0.5 mg的Ranibizumab组在随访期内可快速提高视力，视力分别平均提高了12.7、14.9个字母，并且减轻了CRVO继发的黄斑水肿，安慰剂组视力平均提高了0.8个字母，治疗过程中无一例发生不良反应和并发症。挪威Kinge等[<xref ref-type="bibr" rid="hanspub.15536-ref17">17</xref>] 进行了ROCC研究，即评价Ranibizumab在治疗CRVO继发黄斑水肿方面的有效性。该研究为前瞻性、多中心、随机、双盲、安慰剂对照，随访期6个月，32例患者纳入该研究。结果表明，对于CRVO继发黄斑水肿的患者，每月1次玻璃体内注射Ranibizumab可显著提高视力和减轻黄斑水肿，且连续注射对于维持最初较好的治疗效果非常必要。</p></sec></sec><sec id="s5"><title>3. 联合治疗</title><p>黄斑区格栅样光凝(grid laser photocoagulation, GLP)可有效减轻黄斑水肿、提高RVO继发黄斑水肿视力。GLP机制是光凝直接封闭渗漏的微血管或减少扩张的毛细血管的渗漏，使黄斑小动脉部分狭窄，以减轻黄斑区水肿；光凝在黄斑区外形成一个屏障，拦截视网膜各层间渗液向黄斑无血管区聚集，防止其他血管的渗漏进入中心凹，减少黄斑水肿的来源；黄斑区格栅样光凝破坏大量的光感受器，减少氧耗，从而增加内层视网膜氧分，减少视网膜血流量，减轻视网膜血管渗漏[<xref ref-type="bibr" rid="hanspub.15536-ref18">18</xref>] 。但是单纯的GLP治疗对患者视力提高的作用是有限的，只能在一定程度上缓解部分水肿，可减轻约50%由黄斑水肿引起的视力丧失[<xref ref-type="bibr" rid="hanspub.15536-ref19">19</xref>] 。抗VEGF药物可以快速减轻RVO继发的黄斑水肿，提高视力，但是需要反复治疗。VEGF对于血管生长、舒缩功能和凝血功能等均有影响，玻璃体内注射抗VEGF药物阻断其作用后，可能对眼部的血流产生不良影响，同时，这些药物经血液循环进入全身血液，也可能引起全身其他部位的血管栓塞性疾病。因此玻璃体内注药本身是一个高风险的操作可能出现严重的并发症。频繁注射进一步增加医疗风险，为了减少反复治疗次数并且保证治疗的效果和安全性，联合治疗成为了新的研究热点。</p><p>在黄斑水肿较重时先给予抗VEGF治疗，由于抗VEGF治疗起效快、作用强，可以迅速明显的减轻黄斑水肿，提高视力，而在视网膜水肿减轻时行GLP治疗，可使GLP能以较低的能量更有效的完成，以最小的损伤达到最佳的治疗效果，从而降低治疗的频率、避免复发并且提高RVO黄斑水肿患者的视力。近期有学者将Avastin与GLP联合用于治疗BRVO继发的CME，取得了很好的疗效，且有效减少了平均注射次数，但仍需要更大样本的长期对照研究观察[<xref ref-type="bibr" rid="hanspub.15536-ref20">20</xref>] 。近期张岩雪等[<xref ref-type="bibr" rid="hanspub.15536-ref21">21</xref>] 的研究中，将BRVO合并黄斑水肿患者30例30眼随机分为3组:第1组(10眼)单纯行黄斑区格栅样光凝；第2组(10眼)玻璃体腔注射1次Ranicizumab 0.05 mL/0.5 mg，7 d后行黄斑区格栅样光凝；第3组(10眼)玻璃体腔连续注射3次Ranicizumab 0.05 mL/0.5 mg，间隔1 mo，第1次注射7 d后行黄斑区格栅样光凝。随访6 mo，观察最佳矫正视力及OCT检查黄斑中央厚度。结果显示患者6 mo后视力显著提高，1组平均提高11个字母，2组提高17个字母，3组提高18个字母。OCT显示1组黄斑中央厚度平均降低208.7 μm，2组降低312.9 μm，3组降低326.8 μm。1组中视力提高3行以上1例(10%)，2组有3例(30%)，3组有4例(40%)。从而证明了联合治疗明显优于单独激光治疗，Ranicizumab 1次玻璃体腔内注射联合黄斑区格栅样激光光凝术治疗BRVO并黄斑水肿安全有效。</p></sec><sec id="s6"><title>4. 总结</title><p>多项研究证明抗VEGF药物治疗对RVO黄斑水肿是安全有效的，但其安全性和有效性有待进一步的探讨，需要进行更多有效的大规模临床对照试验，客观评价其治疗结果，进一步明确适应症的选择标准、确定抗VEGF药物的治疗和随访方案、明确终止治疗标准、重视治疗过程的随访和观察。个体化治疗、联合治疗是治疗RVO黄斑水肿的发展趋势。</p></sec><sec id="s7"><title>文章引用</title><p>刘 敏,罗文娟, (2015) 抗VEGF治疗RVO合并的黄斑水肿的研究进展Study Progress of Unti-VEGF Treatment of Macular Edema Induced by Retinal Vein Occlusion. 眼科学,02,42-46. doi: 10.12677/HJO.2015.42008</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.15536-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Salam, A., Da Costa, J. and Sivaprasad, S. (2010) Anti-vascular endothelial growth factor agents for diabetic maculo-pathy. British Journal of Ophthalmology, 94, 821-826.</mixed-citation></ref><ref id="hanspub.15536-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ojima, T., Takagi, H., Suzuma, K., et al. (2006) EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. The American Journal of Pathology, 168, 331-339.</mixed-citation></ref><ref id="hanspub.15536-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Keane, P.A. and Sadda, S.R. (2011) Retinal vein occlusion and macular edema-critical evaluation of the clinical value of ranibizumab. Clinical Ophthalmology, 5, 771-781.</mixed-citation></ref><ref id="hanspub.15536-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Pece, A., Isola, V., Piermarocchi, S., et al. (2011) Efficacy and safety of antivascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Ranibizumab) for naive retinal vein occlusion: 1-year follow-up. British Journal of Ophthalmology, 95, 56-68.</mixed-citation></ref><ref id="hanspub.15536-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Noma, H., Minamoto, A., Funatsu, H., Tsukamoto, H., Nakano, K., Yamashita, H., et al. (2006) Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefe’s Archive for Clinical and Experimental Ophthalmology, 244, 309-315.</mixed-citation></ref><ref id="hanspub.15536-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Noma, H., Funatsu, H., Yamasaki, M., Tsukamoto, H., Mimura, T., Sone, T., et al. (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond), 22, 42-48.</mixed-citation></ref><ref id="hanspub.15536-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Park, S.P. and Ahn, J.K. (2009) Changes of aqueous vascular endothelial growth factor and pigment epithelium-de- rived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clinical Experimental Ophthalmology, 37, 490-495.</mixed-citation></ref><ref id="hanspub.15536-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hufendiek, K., Hufendiek, K., Panagakis, G., et al. (2012) Visual and morphological outcomes of bevacizumab (Avastin) versus ranibizumab (Lucentis) treatment for retinal angiomatous proliferation. International Ophthalmology, 32, 259-268.</mixed-citation></ref><ref id="hanspub.15536-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ciulla, T.A. and Rosenfeld, P.J. (2009) Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Current Opinion in Ophthalmology, 20, 166-174.</mixed-citation></ref><ref id="hanspub.15536-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wroblewski, J.J., Wells 3rd, J.A., Adamis, A.P., Buggage, R.R., Cunningham, E.T., Goldbaum, M., et al. (2009) Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Archives of Ophthalmology, 127, 374- 380.</mixed-citation></ref><ref id="hanspub.15536-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wroblewski, J.J., Wells III, J.A. and Gonzales, C.R. (2010) Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. American Journal of Ophthalmology, 149, 147-154.</mixed-citation></ref><ref id="hanspub.15536-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Rosenfeld, P.J., Fung, A.E. and Puliafito, C.A. (2005) Optical coherence tomography findings after an intravitreal injection of bevaci-zumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surgery Lasers and Imaging, 36, 336-339.</mixed-citation></ref><ref id="hanspub.15536-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Jaissle, G.B., Ziemssen, F., Petermeier, K., Szurman, P., Ladewig, M., Gelisken, F., et al. (2006) Beva-cizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmology, 103, 471-475.</mixed-citation></ref><ref id="hanspub.15536-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Epstein, D.L., Algvere, P.V., von Wendt, G., Seregard, S. and Kvanta, A. (2012) Bevacizumab for macular edema in central retinal vein occlusion: A prospective, randomized, double-masked clinical study. Ophthalmology, 119, 1184- 1189.</mixed-citation></ref><ref id="hanspub.15536-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kriechbaum, K., Michels, S., Prager, F., Georgopoulos, M., Funk, M., Geitzenauer, W. and Schmidt-Erfurth, U. (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: A prospective study. British Journal of Ophthalmology, 92, 518-522.</mixed-citation></ref><ref id="hanspub.15536-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Brown, D.M., Campochiaro, P.A., Singh, R.P., Li, Z., Gray, S., Saroj, N., et al. (2010) Ranibizumab for macular edema following central retinal vein occlusion: Six month primary end point results of a phase III study. Ophthalmology, 117, 1124-1133.e1.</mixed-citation></ref><ref id="hanspub.15536-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kinge, B., Stordahl, P.B., Forsaa, V., Fossen, K., Haugstad, M., Helgesen, O.H., et al. (2010) Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: Results from the sham-controlled ROCC study. American Journal of Ophthalmology, 150, 310-314.</mixed-citation></ref><ref id="hanspub.15536-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Shima, D.T., Adamis, A.P., Ferrara, N., Yeo, K.T., Yeo, T.K., Allende, R., et al. (1995) Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Molecular Medicine, 1, 182-193.</mixed-citation></ref><ref id="hanspub.15536-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Park, S.P. and Ahn, J.K. (2009) Changes of aqueous vascular endothelial growth factor and pigment epithelium-de- rived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clinical Experimental Ophthalmology, 37, 490-495.</mixed-citation></ref><ref id="hanspub.15536-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Salinas-Alamán, A., Zarranz-Ventura, J., Caire González-Jauregui, J.M., Sádaba-Echarri, L.M., Barrio-Barrio, J. and García-Layana, A. (2010) Intravitreal bevacizumab associated with grid laser photocoagulation in macular edema secondary to branch retinal vein occlusion. European Journal of Ophthalmology, 21, 434-439.</mixed-citation></ref><ref id="hanspub.15536-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">张雪岩, 李艳波, 周黎纹, 王晓波, 罗向东 (2014) 玻璃体腔注射雷珠单抗联合激光光凝治疗 BRVO 合并黄斑水肿. 国际眼科杂志, 4, 747-749.</mixed-citation></ref></ref-list></back></article>